KRAS-G12C covalent inhibitors: A game changer in the scene of cancer therapies

Volume: 168, Pages: 103524 - 103524
Published: Dec 1, 2021
Abstract
RAS is the most frequently mutated oncogene in human cancer. Scientists attempted for decades to target this protein or its pathways, however, all the attempts failed and RAS was labeled as "undruggable". With KRAS-G12C covalent inhibitors entering clinical trials, the myth of this "undruggable" RAS is fading away. In 2021, the Food and Drug Administration (FDA) approved the use of Sotorasib (Lumakras) for the treatment of adult patients with...
Paper Details
Title
KRAS-G12C covalent inhibitors: A game changer in the scene of cancer therapies
Published Date
Dec 1, 2021
Volume
168
Pages
103524 - 103524
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.